Clinical trials
Small Cell Lung Cancer clinical trials
Below are recruiting small cell lung cancer clinical trials, each written for real people, not researchers. We’re tracking 1,523 recruiting studies, each written for real people, not researchers, below.
Recruiting studies
- NCT06170788RecruitingPhase 3
New Two-Drug Immunotherapy Combo vs. Standard Immunotherapy for Advanced Lung Cancer
This study compares a new combination of two immunotherapy drugs (sacituzumab tirumotecan plus pembrolizumab) versus pembrolizumab alone for people with advanced non-small cell lung cancer that has a high PD-L1 level (≥50%) and has not been treated yet. The goal is to see if the combination works better than the standard single immunotherapy.
Phoenix, ArizonaAges 18 years+ - NCT06171750RecruitingPhase 1
Study of ANK-101 for advanced solid tumors
This trial tests a new drug, ANK-101, injected directly into tumors to help fight advanced solid tumors that have spread or can't be treated with standard therapies. It may be an option if you have a tumor that can be reached for injection.
Bethesda, MarylandAges 18 years+ - NCT06180005Recruiting
Lung cancer genetic drivers study at CRO Aviano
This study is looking at people with non-small cell lung cancer (NSCLC) to find certain genetic changes that drive the cancer. It may help doctors understand which treatments could work best for you.
Aviano, PordenoneAges Any age - NCT06188650Recruiting
New drug combo for advanced lung cancer after two treatments fail
This trial tests a combination of a targeted chemotherapy bead injection into lung arteries, an oral anti-cancer drug, and an immunotherapy for advanced non-small cell lung cancer that has not responded to two prior treatments. It aims to see if this triple approach can help patients who have limited options left.
Ningbo, ZhejiangAges 18 years+ - NCT06192849RecruitingPhase 2
Furmonertinib after surgery for EGFR 20 insertion lung cancer
This trial tests a targeted pill (furmonertinib) to prevent your lung cancer from coming back after surgery. It is for people with a certain genetic change in their tumor (EGFR exon 20 insertion) and stage IB, II, or IIIA disease.
Chengdu, SichuanAges 18 years+ - NCT06195189RecruitingPhase 1/Phase 2
Sunvozertinib Plus Chemo for EGFR Lung Cancer After TKI Failure
This trial tests a new pill (sunvozertinib) combined with chemotherapy for people with a specific EGFR mutation type of lung cancer whose previous targeted pill stopped working. It aims to see if the combination can shrink tumors or slow the cancer's growth.
Chengdu, SichuanAges 18–80 - NCT06195527Recruiting
Pembrolizumab blood level monitoring for NSCLC
This study checks how well pembrolizumab (Keytruda) works in people with non-small cell lung cancer (NSCLC) by measuring the drug levels in your blood. It aims to see if adjusting the dose based on these levels improves treatment and reduces side effects.
AngersAges 18 years+ - NCT06198868Recruiting
MRD blood test to guide treatment in lung cancer
This trial uses a blood test (ctDNA and CTC) to check for minimal residual disease (MRD) after treatment for stage IIA-IIIC non-small cell lung cancer. The goal is to see if MRD can help predict whether the cancer will come back and guide decisions on extra treatment to prevent recurrence.
Nanjing, JiangsuAges 18 years+ - NCT06205927RecruitingPhase 2
Carbon Ion Boost for Advanced Lung Cancer
This trial tests a new way to give radiation therapy (carbon ion boost) to people with advanced, inoperable lung cancer. The goal is to see if targeting the most aggressive parts of the tumor with a higher dose can improve outcomes.
Shanghai, Shanghai MunicipalityAges 18–80 - NCT06216301RecruitingPhase 3
Electric fields with immunotherapy and chemo for advanced lung cancer
This trial tests adding a device that delivers electric fields (Tumor Treating Fields) to standard immunotherapy and chemotherapy for people with advanced non-small cell lung cancer that has not been treated before. It may help slow tumor growth.
Birmingham, AlabamaAges 18 years+ - NCT06217757RecruitingPhase 1/Phase 2
LDRT, immunotherapy, chemo, and olaparib for SLFN-11 positive SCLC
This trial tests a combination of low-dose radiation, an immunotherapy drug (sugemalimab), chemotherapy, and a targeted drug (olaparib) as a first treatment for people with extensive-stage small cell lung cancer that has a specific marker called SLFN-11. The goal is to see if this combination is safe and works better than standard treatment.
Chengdu, SichuanAges 18–75 - NCT06218914RecruitingPhase 1
Study of a new treatment for KRAS G12D cancers
This trial tests a new type of cell therapy (called TCR-T) that targets a specific genetic change (KRAS G12D) in advanced solid tumors that have stopped responding to standard treatments. It may be an option if your cancer has this mutation and you have a specific tissue type (HLA).
Duarte, CaliforniaAges 18 years+ - NCT06221800Recruiting
Gut bacteria and lung cancer treatment side effects study
This study looks at how the bacteria in your gut (microbiome) might affect how well your lung cancer treatment works and what side effects you experience. The goal is to learn if certain gut bacteria can predict treatment response or side effects for people with advanced non-small cell lung cancer.
Orange, CaliforniaAges 18 years+ - NCT06222489RecruitingPhase 2
HER3 PET scan for advanced EGFR-mutant lung cancer
This study uses a special PET/CT scan to measure a protein called HER3 in your tumors. The scan uses a radioactive version of the drug patritumab deruxtecan (HER3-DXd). This test may help doctors understand how much HER3 is in your cancer and decide if HER3-targeted therapy could work for you.
Amsterdam, North HollandAges 18 years+ - NCT06223711RecruitingPhase 2
Durvalumab with radiation therapy for limited-spread small cell lung cancer
This trial tests a combination of durvalumab (immunotherapy) plus radiation and chemotherapy for people with extensive-stage small cell lung cancer that has only a few distant spots. The goal is to see if this approach helps control the cancer better.
Augsburg, BavariaAges 18 years+ - NCT06224387RecruitingPhase 1/Phase 2
Study of a new drug for advanced solid tumors
This trial tests a new drug, CTS2190, for people with advanced solid tumors that have not responded to or cannot tolerate standard treatments. The goal is to see if the drug is safe and effective.
Luoyang, HenanAges 18 years+ - NCT06225427RecruitingPhase 1
Gilteritinib for advanced ALK-positive lung cancer
This trial tests a drug called gilteritinib for people with a specific genetic type of lung cancer (ALK-positive) that has spread and has been treated before. You may be eligible if you have already tried at least one targeted therapy, and your cancer is still growing.
Los Angeles, CaliforniaAges 18 years+ - NCT06225804RecruitingPhase 1
Study of ABSK112 for advanced non-small cell lung cancer
This trial tests a new drug called ABSK112 for people with advanced non-small cell lung cancer, especially those whose cancer has a specific change in the EGFR gene (exon 20 insertion). The main goals are to see if it's safe and how the body handles it.
Beverly Hills, CaliforniaAges 18 years+ - NCT06227728Recruiting
Predicting immunotherapy response in advanced cancer
This study uses blood and tumor samples to find markers that predict whether immunotherapy will work for people with stage IV cancer. The goal is to better match treatments to patients.
Ho Chi Minh City, Hồ Chí MinhAges 18–80 - NCT06228326RecruitingPhase 1/Phase 2
Study of KB707 for advanced cancers affecting the lungs
This trial tests a new medicine called KB707 for people with advanced cancers that affect the lungs. It uses a virus to deliver a gene that may help your immune system fight the tumor. The study is especially looking at people with lung cancer (NSCLC) or other solid tumors that have spread to the lungs and haven't responded to standard treatments.
Dothan, AlabamaAges 18 years+ - NCT06232265Recruiting
Predicting Immunotherapy Success in Lung Cancer
This study looks at how well a test called LIRAscore can predict whether immunotherapy will work for people with advanced non-small cell lung cancer. You will receive standard immunotherapy (with or without chemotherapy), and researchers will check your tumor samples for certain markers.
Guangzhou, GuangdongAges Any age - NCT06236438RecruitingPhase 2/Phase 3
Livmoniplimab plus budigalimab and chemo for untreated lung cancer
This trial tests a new combination of two immune system drugs (livmoniplimab and budigalimab) plus standard chemotherapy compared to the current standard treatment (pembrolizumab plus chemo) for people with advanced non-small cell lung cancer that has not been treated yet. The goal is to see if the new combination works better at controlling the cancer.
La Jolla, CaliforniaAges 18 years+ - NCT06238882Recruiting
Nitroglycerin plus radiation for EGFR-mutant lung cancer with brain spread
This trial tests whether adding nitroglycerin (a medicine that widens blood vessels) to standard whole-brain radiation helps improve treatment for lung cancer that has spread to the brain. It is for people with a specific gene change (EGFR mutation) in their cancer.
Mexico City, Mexico CityAges 18–85 - NCT06239194RecruitingPhase 1/Phase 2
MdX2001 for advanced solid tumors
This trial tests a new drug, MDX2001, for people with advanced solid tumors that have spread. The study aims to find the best dose and see how well it works.
Denver, ColoradoAges 18 years+
Hear when a new Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.
Common questions
- Are there clinical trials for small cell lung cancer?
- Yes. Clin2 currently lists 1,523 recruiting small cell lung cancer studies from the U.S. registry, each rewritten for real people, not researchers, so you can see what it’s testing and who it’s for.
- How do I know if I qualify for a small cell lung cancer trial?
- Each study lists its eligibility criteria — rules about age, diagnosis, and prior treatments. On every Clin2 trial page we explain these in words written for real people and offer a short, optional pre-screen for a fit read. The study team makes the final decision.
- Does it cost anything to join a small cell lung cancer trial?
- Using Clin2 is always free. Many trials cover the cost of the study treatment and related visits; some reimburse travel. The study team explains exactly what’s covered before you decide.
Related conditions
Beyond the search
We also like to point to nonprofits doing real good in this area. We aren’t affiliated with them — we just admire the work.
- Stand Up To CancerPeople facing cancer across many types, through the research that leads to better treatments.
Clin2 helps you find and understand clinical trials and does not provide medical advice. Study data comes from ClinicalTrials.gov. Talk with your doctor about whether a specific trial is right for you.